Optum Ventures is a venture capital firm focused on transforming healthcare by investing in innovative digital health companies, particularly early to growth-stage startups that leverage data-driven technologies to enhance healthcare delivery, access, and payment systems. Their strategy involves providing capital, along with Optum's extensive healthcare expertise and market presence, to accelerate the growth and market adoption of their portfolio companies' solutions.
Portfolio
21
Fund Size
$2B
Top Stage
Series B
Last 12 Mo
3
Team
Stage Distribution
Portfolio
21 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Gyde | Series C | $60M | Jan 2026 |
| RISA Labs | Series A | $11.1M | Jan 2026 |
| Ambience Healthcare | Growth | $243M | Jul 2025 |
| Nema Health | Series A | $14.5M | Jan 2025 |
| BehaVR | Series B | $13M | Dec 2022 |
| Greater Good Health | Seed | $10M | May 2022 |
| Loop | Series B | $25M | Apr 2022 |
| Rey | Series A | $10M | Jul 2021 |
| Equip | Series A | $13M | Feb 2021 |
| Diameter Health | Series B | $18M | Dec 2020 |
| Kaia Health | Series B | $26M | Jun 2020 |
| LetsGetChecked | Series C | $71M | May 2020 |
| Oxford VR | Series A | $12.5M | Feb 2020 |
| Buoy Health | Series B | $15M | Aug 2019 |
| Health at Scale | Series A | $16M | May 2019 |
| RubiconMD | Series B | $13.8M | Apr 2018 |
| LetsGetChecked | Series A | $12M | Mar 2018 |
| Medallion | Series B | $30M | — |
| DispatchHealth | Growth | $330M | — |
| Alma | Series D | $130M | — |
| Truepill | Series B | $25M | — |
Top Co-Investors
Humana2 shared
HLM Venture Partners2 shared
Deerfield2 shared
.406 Ventures2 shared
F-Prime Capital2 shared
General Catalyst1 shared
Khosla Ventures1 shared
Sequoia Capital1 shared
Martin Ventures1 shared
Health Velocity Capital1 shared
Idinvest1 shared
Balderton Capital1 shared
Heartcore Capital1 shared
Symphony Ventures1 shared
Illumina Ventures1 shared
Transformation Capital1 shared
Qiming Venture Partners USA1 shared
Lightspeed Venture Partners1 shared
Virtue1 shared
Last updated: 1 March 2026